This targeting approach was used, among others, in the fibronectin gene, Ullrich congenital muscular dystrophy (UCMD), and growth hormone deficiency (GHD) type II diseases [72,73,74]. The gene discussed is FN1; the disease is Congenital muscular dystrophy, Ullrich type.